

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A fusogenic vesicle encapsulating at least one therapeutic or immunologically active substance, said fusogenic vesicle comprising a first viral fusion protein, wherein the first viral fusion protein is X-31 hemagglutinin (HA) and at least two different one other viral fusion protein[s] wherein the fusion proteins are derived selected from the group consisting of influenza virus, VSV, SFV, Sendai virus, and HIV [viruses], [and] wherein the at least two different types of one other viral fusion protein[s have] causes fusion at a different fusion characteristics selected from the group consisting of temperature than X-31 HA[and pH].

2. (Original) The fusogenic vesicle according to claim 1, wherein the vesicle is unilamellar.

3. (Original) The fusogenic vesicle according to claim 1 or 2, wherein the encapsulated therapeutic or immunologically active substance is selected from the group consisting of DNA, RNA, siRNA, proteins, peptides, amino acids and pharmaceutically active substances.

4. (Original) The fusogenic vesicle according to claim 3, wherein the encapsulated therapeutic or immunologically active substance is selected from the group consisting of a cosmetic agent, a pharmaceutical drug, an antigen or mixtures thereof.

5-6. (Cancelled)

7. (Currently amended) The fusogenic vesicle according to claim 1, wherein at least one of the viral fusion proteins is cell type specific.

8. (Cancelled)

9. (Currently amended) The fusogenic vesicle according to claim 1, wherein the at least one other viral fusion proteins is ~~are derived~~ from influenza virus.

10. (Currently amended) The fusogenic vesicle according to claim 9, wherein the at least one other viral fusion protein[s are] is selected from the group consisting of [X-31 HA,] PR8/34 and A/Singapore HA.

11. (Previously presented) The fusogenic vesicle according to claim 1, further comprising lipids derived from the group consisting of glycolipids, phospholipids, cationic lipids, synthetic lipids and cholesterol.

12. (Previously presented) The fusogenic vesicle according to claim 11, wherein the lipids comprise POPC and DDAB.

13. (Currently amended) The fusogenic vesicle according to claim 1, further comprising lipids derived from a virus selected from the group consisting of influenza virus, VSV, SFV, Sendai virus and HIV [virus].

14. (Previously presented) The fusogenic vesicle according to claim 13, wherein the lipids are derived from influenza virus.

15. (Original) The fusogenic vesicle according to claim 1, wherein the vesicle has a diameter of between 100 and 300 nm.

16. (Previously presented) The fusogenic vesicle according to claim 1, further comprising a cell-surface receptor, cytokine, growth-factor, antibody, or antibody fragment.

17-38. (Cancelled)